HomeInsightsStock Comparison

Bharat Immunological Biological Corporation Ltd vs Kabra Drugs Ltd Stock Comparison

Bharat Immunological Biological Corporation Ltd vs Kabra Drugs Ltd Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

  • The Latest Trading Price of Bharat Immunological & Biological Corporation Ltd is ₹ 17.3 as of 06 May 15:30 . The P/E Ratio of Bharat Immunological & Biological Corporation Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Kabra Drugs Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Bharat Immunological & Biological Corporation Ltd changed from ₹ 196.47 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Kabra Drugs Ltd changed from ₹ 2 crore on March 2022 to ₹ 26.27 crore on March 2025 . This represents a CAGR of 90.37% over 4 years The revenue of Bharat Immunological & Biological Corporation Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Kabra Drugs Ltd for the Dec '25 is ₹ 30.6 crore as compare to the Sep '25 revenue of ₹ 19.94 crore. This represent the growth of 53.46% The ebitda of Bharat Immunological & Biological Corporation Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Kabra Drugs Ltd for the Dec '25 is ₹ 2.62 crore as compare to the Sep '25 ebitda of ₹ 2.22 crore. This represent the growth of 18.02% The net profit of Bharat Immunological & Biological Corporation Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Kabra Drugs Ltd changed from ₹ -0.55 crore to ₹ 2.57 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Bharat Immunological & Biological Corporation Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Kabra Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Bharat Immunological & Biological Corporation Ltd

  • The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology.
  • BIBCOL was incorporated in 1989.
  • The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets. The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh.
  • BIBCL installed a plant of 100 mln units.
  • Commercial production of the OPV started from Jan'96. The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme.

About Kabra Drugs Ltd

  • Kabra Drugs Limited was incorporated as a Limited Company on August 22, 1989.
  • The Company has set up a Unit at Indore for manufacturing of Ether derivatives which includes Diethyl Ether (Anesthesia), Solvent Ether, Ethyl Chloride Spray (General Anesthesia) and Surgical.
  • The commercial production commenced in 1991.
  • Kabra Drugs Limited is the only manufacturer of Ether derivatives in the State of M.P. tHE Company is presently engaged in the business of Permaculture manufacturing and trading in pharma related products.
  • The Company has 500+ products across India. The Company was incorporated with a mission to enrich the lives through pharmaceutical solutions which are innovative, high-quality and accessible to every family it serves.

FAQs for the comparison of Bharat Immunological & Biological Corporation Ltd and Kabra Drugs Ltd

Which company has a larger market capitalization, Bharat Immunological & Biological Corporation Ltd or Kabra Drugs Ltd?

Market cap of Bharat Immunological & Biological Corporation Ltd is 74 Cr while Market cap of Kabra Drugs Ltd is 62 Cr

What are the key factors driving the stock performance of Bharat Immunological & Biological Corporation Ltd and Kabra Drugs Ltd?

The stock performance of Bharat Immunological & Biological Corporation Ltd and Kabra Drugs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bharat Immunological & Biological Corporation Ltd and Kabra Drugs Ltd?

As of May 6, 2026, the Bharat Immunological & Biological Corporation Ltd stock price is INR ₹17.3. On the other hand, Kabra Drugs Ltd stock price is INR ₹26.21.

How do dividend payouts of Bharat Immunological & Biological Corporation Ltd and Kabra Drugs Ltd compare?

To compare the dividend payouts of Bharat Immunological & Biological Corporation Ltd and Kabra Drugs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions